Acquisition

September 3, 2026 Listing Department, Listing Department, National Stock Exchange of India Limited BSE Limited Exchange Plaza, Plot C-1, Block G, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai - 400 051 Mumbai - 400 001 Symbol: MAXHEALTH Scrip Code: 543220 Sub.: Infusion of funds in Kalinga Hospital Ltd. Ref.: Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Madam, We wish to inform that Renewable Energy and Subsidiary Investment Committee (“RESIC”) of the Company, a duly authorized Committee by the Board of Directors of the Company, at its meeting held today i.e. September 3, 2026, approved to infuse an additional amount of ~₹87.87 Crore, by way of subscription to equity shares on rights basis of Kalinga Hospital Ltd., a subsidiary of the Company. The RESIC meeting commenced at 2.50 pm (IST) and concluded at 3.22 pm (IST). Details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure. This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above Annexure Details with respect to Infusion of funds in Kalinga Hospital Ltd. Particulars Details 1. Name of the target entity, details in brief such Name of Target Company: Kalinga Hospital Ltd. (“KHL”) as size, turnover etc. CIN: U85110OR1990PLC002492 Paid-up Capital: ₹21.54 Crore Revenue from Operation during FY 2025-26: ~₹155.64 Crore 2. Whether the acquisition would fall within KHL being a subsidiary of the Company is a Related Party of the related party transaction(s) and whether the Company. However, the acquisition of additional equity shares promoter/ promoter group/ group companies in KHL, pursuant to the Rights Issue, is exempted as related party have any interest in the entity being acquired? transaction under the provisions of the SEBI (Listing Obligations If yes, nature of interest and details thereof and Disclosure Requirements) Regulations, 2015. and whether the same is done at “arm’s length” Promoter / Promoter group / Group companies do not have any interest in KHL, except to the extent of shares held by the Company in KHL. 3. Industry to which the entity being acquired Healthcare Services belongs 4. Objects and impact of acquisition (including The proposed investment is being made to support the KHL's but not limited to, disclosure of reasons for capital expenditure and modernization programme, strengthen acquisition of target entity, if its business is its clinical and operational capabilities, optimise its capital outside the main line of business of the listed structure and meeting its general corporate requirements. entity) 5. Brief details of any governmental or Not applicable regulatory approvals required for the acquisition 6. Indicative time period for completion of the Within next 15 days acquisition 7. Consideration - whether cash consideration or Cash consideration share swap or any other form and details of the same 8. Cost of acquisition and/or the price at which ~₹87.87 Crore towards the subscription of equity shares of KHL the shares are acquired on rights basis. 9. Percentage of shareholding / control acquired The required details would be available upon allotment of shares and / or number of shares acquired to the Company pursuant to Rights Issue of KHL. 10. Brief background about the entity acquired in NA terms of products/line of business acquired, date of incorporation, history of last 3 years KHL is an existing subsidiary of the Company. turnover, country in which the acquired entity has presence and any other significant information (in brief)